Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting

Schedule of certain segment information

	Year Ended December 31,
	2024		2023
Grant revenue	$	5,174	$	4,529
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		6,840		4,922
AP-PA02: Cystic Fibrosis		236		1,692
AP-SA02: Bacteremia		4,177		4,789
AP-SA02Prosthetic Joint Infection		35		202
Expenses not allocated by projects		2,408		3,042
Total external research and development expenses		13,696		14,647
Research and development personnel expenses		10,764		9,408
Other research and development expenses		9,966		9,715
Total research and development expenses		34,426		33,770
General and administrative expenses:
General and administrative personnel expenses		4,935		2,480
Other general and administrative expenses		8,249		9,169
Total general and administrative expenses		13,184		11,649
Total operating expenses		47,610		45,419
Operating loss		(42,436)		(40,890)
Other income (expense), net		23,520		(28,155)
Net loss	$	(18,916)	$	(69,045)